Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma

被引:0
|
作者
Sarah J. Vinnicombe
Rodney H. Reznek
机构
[1] St Bartholomew's Hospital,Department of Diagnostic Imaging
关键词
Computerised tomography; Hodgkin's disease; Non-Hodgkin's lymphoma; Staging; Lymphangiography;
D O I
暂无
中图分类号
学科分类号
摘要
The last 25 years have seen major changes in the imaging investigation and subsequent management of patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL); accurate staging is vital for prognostication and treatment in both, and particularly in HD. The choice of imaging modality for staging depends on its accuracy, impact on clinical decision-making, and availability. Modern CT scanners fulfil most of the desired criteria. The advent of CT scanning, along with the development of ever more effective chemotherapeutic regimens, has resulted in the virtual demise of bipedal lymphangiography (LAG) as a staging tool in patients with lymphoma. It has rendered superfluous a battery of other tests that were in routine use. This contribution reviews the evidence for the use of CT in preference to LAG. CT accurately depicts nodal enlargement above and below the diaphragm, has variable sensitivity for intra-abdominal visceral involvement and is generally outstanding in depicting the extent of disease, especially extranodal extension. Despite the advances in CT technology, there are still areas where CT performs less well (e.g. disease in normal-sized lymph nodes, splenic and bone marrow infiltration). The influence of technical factors, such as the use of intravenous contrast medium, is discussed. In some instances, CT is not the imaging modality of choice and the place of newer techniques such as MRI and endoscopic ultrasound will be reviewed.
引用
收藏
页码:S42 / S55
相关论文
共 50 条
  • [31] Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
    Wirth, A
    Seymour, JF
    Hicks, RJ
    Ware, R
    Fisher, R
    Prince, M
    MacManus, MP
    Ryan, G
    Januszewicz, H
    Wolf, M
    AMERICAN JOURNAL OF MEDICINE, 2002, 112 (04): : 262 - 268
  • [32] Anticipation in families with Hodgkin's and non-Hodgkin's lymphoma in their pedigree
    Alexandrescu, Doru T.
    Garino, Alexandria
    Brown, Kelly
    Wiernik, Peter H.
    CANCER RESEARCH, 2006, 66 (08)
  • [33] Minimal residual disease in non-Hodgkin's lymphoma
    Schultze, JL
    Gribben, JG
    BIOMEDICINE & PHARMACOTHERAPY, 1996, 50 (09) : 451 - 458
  • [34] Brentuximab vedotin for the treatment of Hodgkin's and non-Hodgkin's lymphoma
    Reagan, Patrick M.
    Friedberg, Jonathan W.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (05): : 609 - 618
  • [35] New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma
    Cheson, Bruce D.
    RADIOLOGIC CLINICS OF NORTH AMERICA, 2008, 46 (02) : 213 - 223
  • [36] TESTICULAR NON-HODGKIN'S LYMPHOMA
    Zugor, V.
    Labanaris, A. P.
    Friedel, S.
    Wullich, B.
    Schott, G. E.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4061 - 4061
  • [37] Sunlight and non-Hodgkin's lymphoma
    Zheng, TZ
    Owens, PH
    INTERNATIONAL JOURNAL OF CANCER, 2000, 87 (06) : 884 - 885
  • [38] Follicular non-Hodgkin's lymphoma
    Hayashi, D.
    Lee, J. C.
    Devenney-Cakir, B.
    Zaim, S.
    Ounadjela, S.
    Solal-Celigny, P.
    Juweid, M.
    Guermazi, A.
    CLINICAL RADIOLOGY, 2010, 65 (05) : 408 - 420
  • [39] Anticipation occurs in familial Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
    Wiernik, PH
    Wang, SQ
    Hu, XP
    Marino, P
    BLOOD, 1997, 90 (10) : 3964 - 3964
  • [40] Non-Hodgkin's lymphoma staging with PET-CT scan
    Setoain, Xavier
    Lopez-Guillermo, Armando
    MEDICINA CLINICA, 2011, 137 (09): : 402 - 404